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Organophosphates (OP) are chemicals found in certain pesticides and in nerve agents such 
as sarin. Toxicity with these agents can lead to death. On August 2013, 1,300 civilians were 
killed using sarin gas in Syria by the Assad regimen. The lack of prepared medical 
facilities, and the availability of appropriate treatment significantly contributed to the high 
percent of causality. Further, worldwide pesticides toxicity affects 3 million people 
annually. Therefore, it is imperative that antidote to treat OP toxicity are readily available 
in a dosage form that is acceptable cost, effective, and user friendly. Atropine sulfate (AS) 
is the first-line antidote for OP toxicity. Since the only emergency dosage forms available 
are parenteral, we developed a sublingual tablet to deliver AS for the initial treatment of 
OP toxicity. AS fast disintegrating sublingual tablets (AS FDSTs) were formulated, 
manufactured, quality control tested, and evaluated for their feasibility for in vitro and ex 
vivo AS diffusion. 
Nine AS FDSTs batches were manufactured by direct compression and tested for 
quality control. Two tablet sizes, group A weighing 150 mg and group B weighing 50 mg, 
were formulated with a range of AS doses, 0 mg (A1 and B1), 2 mg (A2 and B2), 4 mg 
(A3 and B3), and 8 mg (A4, B4a, B4b). AS FDSTs' characteristics were evaluated using 
United States Pharmacopeia (USP) and non-USP tests. AS in vitro diffusion and the ex 
vivo permeation were investigated using synthetic cellulose membrane and excised porcine 
sublingual membrane in Franz cells. The effect of AS load and tablet size on sublingual 
permeation were also evaluated. 
All AS FDSTs batches passed quality control tests, FDSTs disintegrated within 30 
seconds, and AS was dissolved within 60 seconds. In vitro and ex vivo cumulative AS 
(JAUC0-90) and influx (J) increased linearly with increasing AS dose and both results 
correlated linearly. Group B FDSTs had a faster tablet disintegration and higher initial 
permeation (JAUC0-15) than group A FDSTs, which made group B FDSTs a better 
candidate for sublingual administration.  
These AS FDSTs have the potential as an alternative dosage form for OP toxicity 
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 Research Rationale 
The prohibition of mass destruction weapons use, producing, or stockpiling (OPCW, 2005) 
did not stop the extermination of 1,300 civilians using organophosphates (OP) nerve agent 
(sarin) in Syria in 2013 (United-Nations, 2013). Further, the use of OP based pesticides in 
the United States resulted in more than 12,000 toxicity cases from 2011 to 2014 (Bronstein, 
Spyker, Cantilena, Rumack, & Dart, 2012; Mowry, Spyker, Cantilena, Bailey, & Ford, 
2013, 2014, 2015). 
 The cost effectiveness of OP-based pesticides has led to the intense use of these 
products in all agricultural countries (Bertolote, Butchart, & Besbellli, 2004). More than 
37 types of OP pesticides are used in the United States (Delaplane, 1996). Worldwide, 
there are 3 million OP toxicity cases annually (Bertolote et al., 2004).  
Atropine sulfate (AS) intramuscular injection (I.M.) is the recommended antidote 
for the treatment of OP toxicity in all treatment guidelines (Buckley, Dawson, & Whyte, 




1992; Sullivan Jr & Blose, 1992; WHO, 2004; Wiener & Hoffman, 2004). Further, all 
sources agree that a 2-mg dosage of AS must be administered in increasing doses every 
five minutes until atropinization is achieved (Buckley et al., 1994; Eddleston et al., 2008; 
Eddleston et al., 2004; WHO, 2004).  
For the treatment of OP toxicity, a pre-filled AS auto-injector (AtroPen®) produced 
by Meridian Medical Technologies, Inc. (Meridian, 2016a) is the only available AS dosage 
form for out-of-hospital self-administration. Several researchers have highlighted the 
disadvantages of such devices (Altman & Wood, 2014; Bentur, Layish, & Krivoy, 2006; 
Bourbonnais, McMorran, & Wang, 2008; Bryant & Umar, 2014; Chad et al., 2013; Chipps, 
2011; Edwards, Edwards, Simons, & North, 2015; Pouessel et al., 2006; Silverberg & 
Manoach, 2007; Yamane, 1999). Patients at risk of OP are expected to carry multiple 
AtroPen® devices, something that is thought to pose a significant problem for armed 
soldiers (Hague & Derr, 2004; Silverberg & Manoach, 2007; Yamane, 1999). As a result, 
the device’s size limits the number of injections that can be administered (Rawas-Qalaji, 
Simons, & Simons, 2006b), and it is very common for patients to commit errors during 
administration (Altman & Wood, 2014; Bryant & Umar, 2014; Chad et al., 2013). 
Furthermore, injuries due to breakage of the needle is always a possibility (Bentur et al., 
2006; Hague & Derr, 2004; Newmark, 2004; Rawas-Qalaji et al., 2006b). In addition, 
patients with a fear of needles may delay administration (Altman & Wood, 2014). 
Moreover, a lack of sufficient training on the use of auto-injectors can have fatal 
consequences (Topal et al., 2014). Although AtroPen® devices are typically dispensed to 




(Bentur et al., 2006), the device’s cost means that it is unavailable to many potential 
patients. Recently, sarin gas attacks on Syrian civilians with no access to AS resulted in 
1,300 causalities (United-Nations, 2013). The market has no substitute for auto injector 
devices as AtroPen® to administer AS. Based on these drawbacks, we herein investigate an 
alternative, user-friendly, and accessible route of administration for AS, especially for 
civilian populations. 
The use of the sublingual area (SL) for drug administration offers several 
advantages over the use of other absorption sites; it bypasses the caustic environment of 
the stomach and the first-pass metabolism of the liver, which increase the potential for drug 
loss and the need to administer a higher dose (Ghandi & Robinson, 1994; Shojaei, 1998; 
Zhang, Zhang, & Streisand, 2002). Sublingually administered drugs enter the blood 
circulation and become immediately available to produce their pharmacological actions at 
a similar rate and to an analogous extent as drugs provided via the IM route, with the benefit 
of avoiding the need for the invasive administration of injections (Ghandi & Robinson, 
1994; Shojaei, 1998; Zhang et al., 2002). The SL area is far smaller than other absorption 
sites, and the drug is mainly absorbed via passive diffusion through the SL mucosa. This 
limits the number of drugs that can be administered using this route to those of low 
molecular weight and those that are partially soluble in both water and lipids. AS fulfills 
these criteria, making it a viable candidate for SL administration (Ghandi & Robinson, 
1994; Shojaei, 1998; Zhang et al., 2002).  
To set a precedent, a fast-disintegrating sublingual tablet (FDST) formulation has 




results as achieved by EpiPen® auto-injectors (Rawas-Qalaji et al., 2006b). We believe that 
AS has more favorable lipophilic properties for sublingual absorption compared to 
epinephrine. Additionally, the feasibility of the sublingual absorption of AS has previously 
been demonstrated using AS eye drops (Minims® 1%), although not to an optimal extent 
(Heisler et al., 2013; Kanto & Pihlajamaki, 1986). Accordingly, the use of an FDST 
formulation to deliver AS as a treatment for acute OP toxicity can offer several notable 
benefits, which will be described in the following sections. 
 Research Hypothesis 
We hypothesized that the sublingual administration of AS, formulated as FDSTs, is both 
feasible and therapeutic. This route could be a viable alternative approach to the treatment 
of acute OP toxicity. 
 Research Objectives 
The overall aim of this project was to investigate the feasibility of the SL route for 
delivering AS using a FDST formulation for the treatment of OP toxicity. The specific aims 
of the project were as follows: 
1) To develop and manufacture a FDST formulation for the administration of AS. 
2) To evaluate the effect of tablet size and drug load on the physical characteristics 




3) To evaluate in vitro and ex vivo AS diffusion and the effect of increasing AS 
FDSTs’ load and size thereon in terms of its potential for sublingual absorption. 
 Significance of Research and Overall Implications  
Auto-injectors are the only currently available portable drug delivery system for the 
administration of AS in the treatment of acute OP toxicity. However, soldiers at risk of 
attack from nerve agents and farmers that handle OP pesticides require training in the self-
administration of AtroPen® and are expected to carry numerous units, if provided or 
available, for prompt and efficient treatment of OP toxicity (Bertolote et al., 2004). Auto-
injectors require special packaging, handling, and storage space, all of which exacerbates 
the problem of the already high cost of the device. The fear of needles delayed drug 
administration, which worsen OP toxicity complications (Altman & Wood, 2014). 
Repeated training is required to properly use auto-injector devices (Topal et al., 2014). 
The SL route has already been successfully used to administer a range of emergency 
medications. This route’s suitability in such a situation is derived from the excellent 
vascularization of the SL area, its thin mucosal layer, and its direct access to the 
bloodstream (Ghandi & Robinson, 1994; Washington & Washington, 2001; Zhang et al., 
2002). Previously, FDSTs have been effectively developed to deliver up to 40 mg of 
epinephrine in anaphylaxes treatment (Rawas-Qalaji, Simons, & Simons, 2006a; Rawas-
Qalaji et al., 2006b; Rawas-Qalaji, Simons, & Simons, 2007). Additionally, AS sublingual 




are used in a range of clinical applications (Heisler et al., 2013; Kanto & Pihlajamaki, 1986; 
Volz-Zang, Waldhauser, Schulte, & Palm, 1995). The proposed research will constitute the 
first investigation into the potential for formulating FDSTs with AS to be administered via 
the SL route, using a specifically designed dosage form, for the treatment of acute OP 
toxicity.  
These AS FDSTs will have several benefits, notably that they require little or no 
training for their sublingual administration. Patients will not be hesitant about self-
administering these tablets, and will have no anxieties or fears over needles, unlike with 
the auto-injectors. The tablets’ small size will allow users to carry and store multiple 
dosages. Production costs will also be kept within reasonable limits as a result of the tablets 
being manufactured with sufficient hardness to allow for shipping and handling without 
the need for special packaging and handling instructions. Finally, administration errors and 
injuries will be far less likely. 
These tablets potentially have several significant advantages over AtroPen®, which 
will make them more accessible for civilians at risk of OP exposure. The production costs 
should be lower, allowing them to be stocked by every farm and community health center 
in high-risk areas. This will reduce instances of fatalities from OP toxicity, greatly 
enhancing overall health outcomes and disease management. The prognosis and treatment 
outcomes of OP patients should also be improved as treatment can be initiated at an earlier 
stage, with no delays caused by patients having to reach a hospital. In all, compared to 




effective dosage form, with fewer handling and storage limitations, for the treatment of 
acute OP toxicity.  
 Barriers and Issues 
It is natural that several obstacles will be encountered in the development of any new 
dosage form, and these will need to be addressed. One of the main challenges in this 
research was to identify standardized methods of evaluating the characteristics of orally 
disintegrating tablets (ODTs). The United States Pharmacopeia (USP) lists standardized 
approaches to the characterization of disintegration time (DT) for regular tablets, which, 
unlike ODTs, require relatively long periods to disintegrate and dissolve (USP/NF, 2016a). 
In addition, the aim of the methods listed by the USP is to determine whether the tablets 
meet the claimed DT. To resolve this problem, we invented a novel disintegration apparatus 
and procedure that can recognize and record minute differences in the DT between 
formulations.  
For the dissolution test, the USP describes four different apparatuses to test the 
accuracy of the labeled dissolution time: basket apparatus, paddle apparatus, reciprocating 
cylinder apparatus, and flow-through cell apparatus (USP/NF, 2016b). None of these are 
suitable for the development of ODT formulations. For our purposes, the necessary 
dissolution apparatus should be capable of measuring the percentage of the drug that is 




satisfy these requirements, a previously developed dissolution apparatus was used that has 
such capabilities (Rachid, Rawas-Qalaji, Simons, & Simons, 2011). 
 Assumptions and Limitations 
According to the literature, the porcine sublingual membrane (PSM) shares similar 
anatomical and physiological properties with its human sublingual membrane (Birudaraj, 
Berner, Shen, & Li, 2005; Goswami, Kokate, Jasti, & Li, 2013; Ong & Heard, 2009; Volz-
Zang et al., 1995). Therefore, we assumed that the use of a PSM would offer an effective 
representation of AS permeability through the human sublingual membrane. As variability 
exists in human SL permeation, we assumed that similar variability would result in 
permeation of the same dosage form when using a PSM. Additionally, PSM thickness is 
variable within the same membrane, causing different influxes at various points thereon. 
Accordingly, we deployed a larger diffusion cell diameter to enable the use of almost the 
entire membrane, which is more relevant for human administration. 
 Chapter Summary 
The main motivation for conducting this project was the number of yearly casualties caused 
by OP toxicity arising from agricultural or military operations. The aim of the project is to 
investigate the feasibility and potential of using FDSTs to administer AS sublingually in 
the treatment of OP toxicity and other medical emergencies. The novelty of this research 




parenteral injections. In sum, AS FDSTs could provide a practical, user-friendly, and cost-









 Chapter Overview 
This chapter consists of a description of a literature review that was conducted to locate 
the most up-to-date information about OP, AS, the limitations of current AS dosage forms, 
the SL route, and ODT. An overview is given of OP types and their characteristics; in 
addition, the OP toxicity’s etiology, epidemiology, mechanism, and available treatments 
are summarized. A review is conducted of AS clinical uses and dosage forms, with a focus 
on emergency forms for OP toxicity treatment. We then elaborate on the anatomical and 
physiological convenience of the SL route for rapid drug delivery. The chapter concludes 
with a general discussion of ODT types and their uses, with an emphasis on FDSTs.  
 Organophosphates 
OP are a group of chemical compounds with different substitutes for phosphoric acid esters 
(Newmark, 2004; Zhao & Yu, 2013). The OP name stems from the presence of the 




1936, Gerhard Schroeder, a German chemist, developed the OP-related tabun; originally 
this was a pesticide, but its extreme toxicity led him to develop it into a chemical weapon 
called a “nerve agent” (Croddy & Wirtz, 2005a).  
 
 
Figure 1. Basic chemical structure of organophosphates. 
R1, R2, and R3 represent the chemical functional groups that define the intensity of OP 
toxicity, and physical properties.	
 Mechanism of action of Organophosphate toxicity 
The term “organophosphate toxicity” refers to the cholinergic toxicity resulting from the 
deactivation of the acetylcholinesterase (AChE) (Eddleston et al., 2008; Eddleston et al., 
2004). Acetylcholine (ACh) is a neurotransmitter (Figure 2) that is involved in the 
transfer of electrochemical signals from the spinal cord, via the preganglionic autonomic 
nervous fibers, to the ganglions. It then transfers signals from the ganglions, via the 
postganglionic parasympathetic nervous fibers, to the cardiovascular system, glands, and 
smooth muscle in numerous tissues (Rang & Ritter, 2016; Westfall & Westfall, 2010). 
ACh is synthesized in cholinergic nerves and stored in the nerve terminals; when the 
latter are depolarized, ACh is released into the synaptic cleft (Rang & Ritter, 2016; 
Westfall & Westfall, 2010). The instant that ACh transduces a signal, AChE hydrolyzes it 
to choline and acetic acid (also known as acetate) in less than a millisecond (Rang & 
Ritter, 2016; Westfall & Westfall, 2010). AChE is mainly attached to the postsynaptic 






Figure 2. ACh chemical structure. 
The similarity between the carbonyl C=O group in the ACh structure and the phosphate 





Figure 3. ACh synthesis and metabolism. 
This scheme depicts the ACh lifecycle. (1) ACh is formed from choline and acetyl CoA. 
(2) In the synaptic cleft, ACh is rapidly broken down by the enzyme AChE. (3) Choline is 






Figure 4. Role of AChE in the hydrolysis of ACh. 
The positively charged nitrogen in the ACh molecule is attracted to the anionic site on the 




ACh has two functional groups—the carbonyl (C=O) in the acetyl part and the 
quaternary nitrogen in the choline part—and AChE has two active sites, the anionic site 
and the esteratic site (Figure 4) (CDC, 2010). The quaternary nitrogen of ACh interacts 
electrostatically with AChE’s anionic site, whereas the carbonyl group of ACh interacts 
with the esteratic site of AChE’s hydroxyl group. The unstable intermediate then decays, 
liberating choline which is reused to regenerate ACh (Rang & Ritter, 2016; Wiener & 
Hoffman, 2004). Two types of receptors react with ACh: nicotinic receptors and 
muscarinic receptors. Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion 
channels that are categorized into two subspecies: nicotinic-muscular (Nm), which are 
distributed in skeletal neuromuscular junctions, and nicotinic-neural (Nn), which are 
distributed in the autonomic ganglia, the adrenal medulla, and the central nervous system 





receptors (mAChRs) are part of the G-protein coupled receptor (GPCR) family and are 
classified into five subspecies, numbered M1 to M5 (Rang & Ritter, 2016; Westfall & 
Westfall, 2010). When activated by ACh, mAChRs release/inhibit various intracellular 
signaling molecules leading to vital physiological responses (Rang & Ritter, 2016; Westfall 
& Westfall, 2010). An understanding of the fundamental role of ACh in mammalians is 
essential for forecasting the results of AChE inhibition (Eddleston et al., 2008; Mathias & 
Bannister, 2013; Rang & Ritter, 2016; Westfall & Westfall, 2010; Wiener & Hoffman, 
2004). 
The quantitative structure-activity relationship (Q-SAR) of OP suggests that their 
toxicity is directly proportional to the hydrophobicity of the compound (Zhao & Yu, 2013). 
When an OP enters the body, the O=P bond competes with the C=O of ACh for the serine 
at the esteratic site of AChE (Wiener & Hoffman, 2004; Zhao & Yu, 2013). The 
nucleophilic hydroxyl group (-OH) of the serine residue on the active site of AChE attacks 
the electrophilic O=P center of the OP, forming a highly stable covalent bond (Westfall & 
Westfall, 2010; Wiener & Hoffman, 2004; Zhao & Yu, 2013). At this point, the 
phosphorylated AChE is inactive and cannot hydrolyze ACh because ACh binding is 
blocked by the bonded OP. Certain OP release a functional group after a given length of 
time, which strengthens the formed covalent bond through a process termed “aging” (Sidell 














































































































































































 Etiology and epidemiology of organophosphates’ toxicity 
OP toxicity can result from exposure to either of two main sources: nerve agents and 
pesticides. Although an additional source of exposure is medications derived from OP, this 
type of exposure rarely leads to fatal complications and will not be discussed here. 
Nerve agents 
Although the term “nerve agents” includes, by definition, any material that can intoxicate 
the nervous system (Croddy & Wirtz, 2005a), in reality only OP-based weapons are 
considered nerve agents. Examples of the latter include tabun, sarin, soman, and VX (Table 
1). As a result of the hazards associated with stockpiling and transporting nerve agents, 
they are produced as binary, rather than unitary, compounds. Whereas the end result of the 
unitary compounds involves lethal OP, the binary compounds are produced in the form of 
two “safer” separate compounds that, when mixed, produce a fatal compound (Croddy & 
Wirtz, 2005a; WHO, 2004).  
The use of weapons of mass destruction in warfare was forbidden by the Hague 
Conventions of 1899 and 1907, and the Geneva Protocol of 1925 (Croddy & Wirtz, 2005a; 
OPCW, 2005; WHO, 2004). Although OP were not deployed in World War II, many 
countries nevertheless developed and stockpiled nerve agents (Sidell & Borak, 1992). The 
UN classified OP nerve agents as weapons of mass destruction through Resolution 687 





prohibited their production (as either unitary or binary compounds) and their stockpiling 
(CDC, 2010). 
 

























Unfortunately, the categorization of nerve agents as weapons of mass destruction 
and the banning of their manufacture, stockpiling, and use in wars has not been enough to 
stop their use. The first documented use of a nerve agent (sarin gas) occurred in the first 
Gulf War between Iraq and Iran, resulting in over 40,000 deaths (Newmark, 2004). The 
second recorded incident was their use in a Tokyo subway by a terrorist group, leading to 
13 deaths and 50 injuries in 1994 and 1995 (Yanagisawa, Morita, & Nakajima, 2006). Most 
recently, the Assad government has used sarin against the people of Syria, causing 1,300 
deaths in Ghouta (Johnston, 2016; United-Nations, 2013). 
Pesticides 
The dangerous effect of OP toxicity from pesticides is also well documented (Bertolote et 
al., 2004; Gallo & Lawryk, 1991; Langley & Mort, 2012). The effectiveness of OP in this 
area is the main reason for their use in all agricultural countries, including the United States. 
Examples of OPS found in pesticides include dichlorvos, malathion, parathion methyl, and 
chlorpyrifos (Table 2). In low-income countries, the lack of medical facilities in rural areas 
is compounded by the fact that the use of pesticides is not routinely governed by rigorous 
safety procedures. Unfortunately, safer pesticides are less effective and more expensive, 
which limits their use in developing nations (Bertolote et al., 2004; WHO, 2004). Thus, 
























OP pesticides are readily available in large quantities at major farms, leading to 
their common use in instances of suicide and homicides (Bertolote et al., 2004). Accidents 
caused by OP pesticides toxicity result in millions of civilian deaths worldwide every year. 
According to the WHO, worldwide there are 3 million OP toxicity cases annually, of which 
250,000 end with the victim’s death. Worldwide, 900,000 suicide cases are recorded 
annually, 60% of which involve poison with OP (Bertolote et al., 2004). Higher mortality 
rates have been recorded in low-income countries that lack equipped medical centers in 





In the United States, more than 37 types of OP pesticides are used in agriculture 
(Delaplane, 1996). More than 12,000 OP toxicity cases were reported between 2011 and 
2014, according to the Annual Report of the American Association of Poison Control 
Centers’ National Poison Data System (NPDS) (Bronstein et al., 2012; Mowry et al., 2013, 
2014, 2015). 
 Signs and symptoms of organophosphate toxicity  
Not all OP toxicity symptoms are related to the inhibition of AChE; different OP agents 
cause varying “non-cholinergic” symptoms, some of which are chronic while others are 
acute. However, most result from ACh accumulation in the synaptic cleft (cholinergic 
toxicity). The manifestations and intensity of this process are not necessarily the same with 
every OP. As discussed in the subsection “Organophosphate toxicity’s mechanism,” ACh 
stimulates two types of receptors: nicotinic and muscarinic. Researchers use two acronyms, 
“SLUDGE” and “DUMBELLS,” as mnemonics to specify AChE inhibitor toxicity 
symptoms: salivation, lacrimation, defecation, diaphoresis, gastric emesis, diarrhea, 
urination, miosis, bradycardia, and bronchospasm (Eddleston et al., 2008; Eddleston et al., 
2004; Mathias & Bannister, 2013; Newmark, 2004; Westfall & Westfall, 2010; WHO, 
2004; Wiener & Hoffman, 2004):  
1. Eye: ACh activates the muscarinic receptors in the eye, causing constriction 





the ciliary muscle. Excessive lacrimation is another common symptom of OP toxicity 
in the eye. 
2. GI tract: Muscarinic receptors control smooth muscle contractions; over-
stimulation of these receptors on muscles leads to an increase in gastric acid release, 
vomiting, and diarrhea.  
3. Respiratory system: Bronchoconstriction, bronchorrhea, rhinorrhea, and 
diaphragm paralysis are the main symptoms that are directly caused by autonomic 
overstimulation as a result of OP toxicity. One of the most lethal consequences of the 
latter is suffocation from choking caused by excessive saliva secretions. Also, paralysis 
of the diaphragm prevents breathing as well. 
4. Heart: At high OP toxicity levels the effect of vagal nerve stimulation on the 
heart causes bradycardia. Hypotension, meanwhile, is a result of the vasomotor, 
bradycardia effect, and vasodilation.  
5. OP toxicity effects on other organs: Repetitive urination, excessive sweatiness 
and salivation, and fasciculations and paralysis of the muscles are other common 
symptoms of OP toxicity. 
 Treatment 
A range of guidelines have been published regarding the treatment of OP toxicity 
(Eddleston et al., 2008; Eddleston et al., 2004; Mathias & Bannister, 2013; Moshiri, 





WHO, 2004; Wiener & Hoffman, 2004). In these guidelines, treatment is divided into two 
stages, emergency and follow-up, of which the former is aimed at saving patients’ lives. 
The emergency treatment, which must commence as soon as OP toxicity symptoms are 
recognized or suspected, includes:  
1. Removal of the patient from the contaminated area and decontamination of 
his/her body and clothes. The medic must also decontaminate himself or herself 
(Eddleston et al., 2008; Eddleston et al., 2004; Wiener & Hoffman, 2004).  
2. Checking the patient’s airways, breath, and cardiovascular system (ABC) 
(Eddleston et al., 2008; Eddleston et al., 2004; Wiener & Hoffman, 2004).  
3. The injection of AS is an essential stipulation in every emergency guideline. 
Generally, a 2-mg injection is used initially; some guidelines (such as those of the 
WHO) advise doubling the dose every five minutes until the OP toxicity symptoms 
disappear and “atropinization” symptoms emerge (Eddleston et al., 2008; Eddleston et 
al., 2004; Wiener & Hoffman, 2004). 
Then, the follow-up treatment begins at the medical center or emergency room, 
which offers the ability to identify the toxicant material and monitor the physiological 
responses. Treatment includes the following steps: 
1. The administration of pralidoxime or any recommended oxime derivatives: 
Oximes are designed to attack the phosphate moiety of the OP to release the 
hydroxyl group from the esteratic site on the AChE enzyme. This leads to 
the reactivation of the AChE allowing it to commence its physiological 





already “aged,” reactivation is unlikely to occur (Eddleston et al., 2008; 
Eddleston et al., 2004; Wiener & Hoffman, 2004). Several researchers have 
questioned the viability of oxime compounds as OP toxicity antidotes 
(Bentur et al., 2006; Buckley et al., 1994; dos Santos et al., 2011; Petroianu, 
Hasan, et al., 2007; Yanagisawa et al., 2006). Further, oxime compounds are 
highly charged and cannot prevent OP CNS-mediated toxicities (Petroianu, 
Nurulain, et al., 2007). However, the right selection for the oxime derivative, 
based on OP that caused the toxicity, is the cornerstone of the treatment 
(Table 3) (Croddy & Wirtz, 2005b).  
 
Table 3. Comparison of oximes and their effectiveness in countering nerve agent toxicity 
Oxime Sarin Tabun Soman VX 
2-PAM-Cl + + 0 + 
Obidoxime + + + + + 0 + + + 
HI-6 + + + + 0 + + + + + + 
HS-6 + + + 0 + + + + 




2. Treatment of seizures: Certain nerve agents can cause seizures, for which the 
main treatment is benzodiazepines (WHO, 2004; Wiener & Hoffman, 2004).  
3. Overnight hospitalization is essential to monitor those OP agents that are 
released slowly. Some OP are lipophilic compounds that are distributed and stored in 





initial exposure. Accordingly, blood levels may not be an absolutely reliable source for 
tracking these OP presence in the body (WHO, 2004; Wiener & Hoffman, 2004).  
4. Administration of human butyrylcholinesterase (HuBChE): This is the only 
clinically considered OP toxicity prophylaxis that is effective if administered prior to 
exposure. However, repeated doses are required for this approach to remain viable over 
protracted periods (Iyer, Iken, & Leon, 2015). 
 Atropine Sulfate 
Although atropine was first isolated from Atropa belladonna (Solanaceae) by Heinrich 
Mein in 1831 (Evans, 2002; Steenkamp, Harding, Heerden, & Wyk, 2004), it was not until 
1901 that it was chemically synthesized for the first time, by Richard Willstatter (RSC, 
2013). Atropa belladonna, commonly known as deadly nightshade or the “poison black 
cherry,” was introduced into the London Pharmacopoeia in 1809; it is the source of the 
tropane alkaloids, including atropine (Evans, 2002; Steenkamp et al., 2004). The London 
Pharmacopeia (an encyclopedia) was first issued in London in 1621; the last edition was 
published in 1851. 
 Physical and chemical properties 
The basic alkaloid, atropine, is a racemic mixture of a tertiary amine that was named 
by the International Union of Pure and Applied Chemistry and registered by the American 





[3.2.1]oct-3-yl ester, also referred to as d,l-hyoscyamine. Atropine is an ester consisting of 
tropic acid and tropine (Brown & Laiken, 2010) (Figure 6). Its molecular formula is 
[C17H23NO3], and its molecular weight is 289.37. One gram of basic atropine dissolves in 
455 ml of water at room temperature (RSC, 2013). Because of the rather low solubility 
profile of atropine, atropine sulfate monohydrate (AS) takes its place as the active 
ingredient in currently available dosage forms. The AS molecular formula is 
[(C17H23NO3)2.H2SO4.H2O], and its molecular weight is 694.84. Its pKa is 9.8 and a 2% 
AS solution in water has a pH of 4.5 to 6.2. One mL of water can dissolve up to 2.5 g of 




Figure 6. Chemical structure of Atropine. 
 
 
AS pharmacological action of AS is due to the levo-structure form (Zhao & Yu, 
2013). Q-SAR studies have shown that neither tropic acid nor tropine alone has noticeable 
antimuscarinic activity; in addition, the free [–OH] group in the tropic acid element plays 





 Pharmacology and pharmacodynamics 
AS is a selective, competitive blocker for all muscarinic receptor subtypes, with the same 
affinity for all five subtypes (Brown & Laiken, 2010). ACh interacts with muscarinic 
receptors to initiate consequential physiological responses. As a result, repeated doses of 
AS are required to compete with the excess amounts of ACh produced following OP 
toxicity (Eddleston et al., 2008; Eddleston et al., 2004).  
In short, AS effects counteract those of the OP actions that are mediated by 
excessive actions of ACh at muscarinic receptors. The former acts against the secretory 
effect of the latter on the salivary, lacrimatory, and sweat glands, and dries their secretions. 
AS also reverses the OP-induced contraction of the bronchial, eye, gastrointestinal tract 
(GIT), and urinary bladder muscles. In addition, AS induces changes to the heart rate, based 
on the dosage (Elsevier, 2015). 
“Atropinization” is a term used to refer to the signs and symptoms of atropine 
toxicity (Bentur et al., 2006; Eddleston et al., 2004; Wiener & Hoffman, 2004). When 0.5 
mg of AS is injected, the heart rate decelerates slightly, the mouth dries up, and the skin 
stops sweating. A 1-mg dose speeds the heart rate, triggers a thirsty feeling caused by 
dryness of the mouth, and mildly enlarges the pupils. A 2-mg dose causes palpitations, 
intense mouth dryness, and pupil dilatation accompanied by paralysis of accommodation. 
With a 5-mg dose, speaking and swallowing become difficult; the patient will also suffer 
from hot skin, difficulty in urinating, headaches, and reduced gut movement. At 10-mg 





2010; Heath, 2002; Meridian, 2016a). Excessive atropine can lead to death. AS should be 
used carefully in children as they are particularly sensitive to the actions of the drug 
(Elsevier, 2015). 
Even though many more potent anti-muscarinic medications are available, AS is 
the preferred option as an antidote for OP toxicity. It can be easily titrated based on its 
toxicity symptoms, which are the opposite of those of OP, and it is less toxic than other 
agents (Buckley et al., 1994; Croddy & Wirtz, 2005a; Eddleston et al., 2008; Eddleston et 
al., 2004; Newmark, 2004; WHO, 2004; Wiener & Hoffman, 2004). 
 Pharmacokinetics 
Hinderling, Gundert-Remy, and Schmidlin (1985) investigated the pharmacokinetic profile 
of AS (n=3) after intravenous administrations of 1.35 and 2.15 mg doses. These researchers 
found that AS distribution kinetics are dose-dependent. Two-compartmental models of 
biphasic disposition were observed, with an apparent half-life of 1 minute (α) and 140 
minutes (β), respectively. At steady state, the apparent volume of distribution was 210 L, 
indicating extensive tissue binding. They also found that AS exhibited first-order 
elimination kinetics and that its renal plasma clearance was 660 mL/min. The AS 
metabolite, tropine, represented 29% of the AS doses found in urine (Hinderling, Gundert-
Remy, & Schmidlin, 1985). AS is a highly soluble salt in water (2.1 g/mL) and is classified 
as class I/III on the biopharmaceutical classification system (Lindenberg, Kopp, & 





(Minims® 1%), which are used for the death rattle (sounds produced usually by someone 
near death as a results of respiratory secretions) and pediatric sialorrhea (hypersalivation) 
(Heisler et al., 2013; Protus, Grauer, & Kimbrel, 2013; Rapoport, 2010). 
 Clinical uses and dosage forms 
AS has a wide range of clinical uses, both labeled and off-labeled. Ophthalmologists 
administer AS drops to induce mydriasis and cycloplegia, and to treat uveitis (eye pigment 
layer inflammation) and iritis (Elsevier, 2015). AS is also used to prevent lung aspiration 
during surgical operations, as well as (Elsevier, 2015) for irritable bowel syndrome 
(Elsevier, 2015). The main applications for the use of AS in emergency situations involve 
bradycardia and cholinergic toxicity (Brown & Laiken, 2010). OP toxicity is a type of 
cholinergic toxicity, for which AS is one of the main antidotes (Heath, 2002; Meridian, 
2016a, 2016b; Wiener & Hoffman, 2004). 
 Limitation of Current Atropine Sulfate Dosage Form 
 Prefilled auto-injectors of atropine sulfate 
The prefilled auto-injectors of AS alone (AtroPen®), or in combination with oximes (a 
group of medications intended to reactivate acetylcholinesterase), such as pralidoxime 
(DuoDote®), are prescribed as an antidote for OP toxicity (Eddleston et al., 2008; Eddleston 





mg, 0.5-mg, or 0.25-mg AS doses by Meridian Medical Technologies (Meridian, 2016a). 
This company also produces another auto-injector device, DuoDote®, which provides 2.1 
mg of AS in 0.7 mL of solution and 600 mg of pralidoxime chloride in 2 mL using two 
chambers and one needle device (Meridian, 2016b).  
The fact that low-income farmers who are exposed to pesticides may not be able to 
afford AtroPen®’s price ($37 per device) appears to be more of an issue, rather than 




Figure 7. Image of 2.1-mg / 0.7-mL atropine sulfate auto-injector device (AtroPen®). 
 
 Investigational atropine sulfate dosage forms 
Because of the invasiveness of the injection, and the limitations of AtroPen® as described, 
a non-invasive form of AS delivery was investigated in a clinical study for acute OP 
toxicity management. This adopted a pulmonary route, using an inhaler (Corcoran, 
Venkataramanan, & Hoffman, 2013). According to the results, five puffs of the atropine 





using inhalers to deliver adjunctive doses only following the administration of atropine via 
auto-injectors.  
In another study, Ali, Jain, and Iqbal (2009) performed a clinical trial to investigate 
the efficacy of a nano-AS dry powder inhaler as an OP toxicity antidote using the 
pulmonary delivery system. These researchers showed that a 6-mg AS inhaler exhibited a 
comparable pharmacokinetic profile to that of a 2-mg intramuscular injection (Ali, Jain, & 
Iqbal, 2009). 
Kumar, Vijayaraghavan, and Singh (2001) investigated the antagonistic 
effectiveness of an atropine nasal aerosol spray against OP poisoning in terms of the 
cardiovascular and respiratory variables in rats; it was shown that the nasal administration 
of AS was equally as effective as an intraperitoneal injection (Kumar, Vijayaraghavan, & 
Singh, 2001). 
 Sublingual administration of atropine sulfate 
The sublingual absorption of AS has been tested for other clinical applications, using an 
eye drop formulation only (Minims® 1%) (Heisler et al., 2013; Kanto & Pihlajamaki, 1986; 
Volz-Zang et al., 1995). For OP toxicity treatment, the only SL administration attempt was 
by injecting AS under the tongue, a highly invasive method. Indeed, the time needed for 
maximum concentration (Tmax) was less than the intramuscular injection of AS (injected 





 The Sublingual Route 
 Anatomy and physiology 
The oral cavity is one of the most convenient routes for the administration of medications 
as either a pre-gastric or gastric delivery. It is composed of the lips, buccal, tongue, mouth 
floor, and hard and soft palates (Ghandi & Robinson, 1994; Shojaei, 1998; Zhang et al., 
2002). The cavity is lined with a mucosal layer that varies in composition from site to site. 
The outermost layer of the oral mucosa is a stratified squamous epithelium that provides 
protection for the cavity. Although the epithelial layer of the gum and hard palate is 
keratinized, the buccal, soft plate, and SL areas contain no keratin. The epithelial cells lie 
on a basement membrane that is supported by a connective tissue known as lamina propria; 
this is followed by the submucosa as the innermost layer. The lamina propria provides 
physical support by collagen and it receives blood supply through the external carotid 
artery. The jugular vein collects blood from all capillaries returning blood into the main 
circulation (Ghandi & Robinson, 1994; Shojaei, 1998; Zhang et al., 2002) (Figure 8). The 
SL area has the thinnest mucosal lining of all oral mucosa areas, leading to a faster rate of 
absorption from the oral mucosa; the SL area also receives a greater amount of blood than 







Figure 8. The anatomy of the sublingual area (Ghandi & Robinson, 1994). 
Reprinted with permission (Appendix: Copyrights Permissions) 
 Advantages and disadvantages of sublingual administration 
The use of the oral mucosa for pre-gastric drug administration offers several advantages 
over other routes from a physiological, patient-centered, clinical, and industrial points of 
view. Physiologically, it bypasses the stomach and the intestine, and circumvents first-pass 
metabolism by the liver; this reduces the dose required. The administered drug directly 
enters blood circulation and is instantly available for pharmacological action, obviating the 
need for invasive administration routes such as parenteral injections (Ghandi & Robinson, 





From the patient’s perspective, SL administration does not require specialized 
training for dosage intake, as is the case for parenteral or inhaler-based forms. The 
convenience of the SL dosage form enhances patient compliance, as no water is needed to 
dissolve the tablets. A further benefit of the SL dosage form is the lack of any psychological 
barrier caused by fear of the needle, further improving compliance (Altman & Wood, 
2014).  
In clinical terms, many drugs are delivered sublingually for emergency situations. 
SL tablets can be administered as soon as an incident occurs, at any location, with no need 
to reach an emergency room. Nitroglycerin and nifedipine are two examples of well 
documented and successful emergency medications delivered in the form of SL tablets 
(Singh et al., 2012; USP/NF, 2016h). 
The manufacturing and packaging of SL tablets, as is the case with most solid oral 
tablets, is more cost-effective than parenteral dosage forms. There is no need for 
specialized packaging and monitoring of temperature to maintain the dose units.  
However, it is not possible to use the oral mucosa pathway in the administration of 
all medications, because it only has a small surface area for absorption. Also, there is only 
a limited volume of saliva, which is required to disintegrate and dissolve the dosage form 
(Zhang et al., 2002). In addition, the natural swallowing reflex can wash out the drug from 
the pre-gastric to the gastric absorption route. These limitations mean that only medications 
that are water-soluble and therapeutically effective in small doses can be formulated for 
SL absorption (Nakajima et al., 2014; Wang & Chow, 2014). Although the physiological 





ingredients (APIs), the SL mucosa is restricted by its toleration of a narrower pH range 
(Nakajima et al., 2014). Further, the absorption mechanism in the oral mucosa involves 
passive diffusion—either transcellular or paracellular—which reduces the number of drugs 
that are eligible to be passively diffused (Ghandi & Robinson, 1994; Shojaei, 1998; Zhang 
et al., 2002). Finally, because the absorption site is adjacent to the taste site (the tongue), 
the medication’s taste may influence the formulation of the SL dosage form (Wang & 
Chow, 2014).  
 Orally Disintegrating Tablets 
ODT are a user-friendly drug delivery system that helps patients such as geriatrics and 
children, with swallowing problems, by combining the ease of oral administration of 
liquids with the practicality of tablets (Senel, Rathbone, Cansiz, & Pather, 2012). ODT can 
be a substitute for ordinary tablets or liquid dosage forms, to systemically deliver APIs in 
a shorter time, and it also avoids first-pass metabolism of enteric absorption (Kraemer, 
Gajendran, Guillot, & al., 2012). ODT could conceivably replace the invasive parenteral 
injection dosage form currently used for emergency applications (Rawas-Qalaji et al., 
2006b). Examples of ODT manufacturing techniques include direct compression, 
lyophilization, spray drying, molding, melt granulation, sublimation, and orally 
disintegrating thin films (Senel et al., 2012). These tablets are broken down in the oral 
cavity by one of three mechanisms: dissolution (melting), disintegration, or a combination 





filler such as mannitol or other sugar-based excipients (Armstrong, 2009). Disintegration 
occurs when non-soluble excipients are deployed, such as microcrystalline cellulose or 
most cellulose derivatives (Guy, 2009; Hapgood & Obara, 2009; Podczeck, 2009). 
 Orally disintegrating tablets for emergencies 
Although ODT can be deployed to reduce the lag time between dosage form administration 
and the API reaching the bloodstream, this can only be achieved if the absorption site is 
the oral cavity itself (mainly sublingual). Because the API has characteristics that are 
needed for SL administration, the tablet should release it instantly. Out of all the ODT 
manufacturing techniques that yield rapid API release, direct compression and wet 
granulation are the only methods able to produce hard tablets that can withstand vigorous 
handling without the need for specialized packaging (Senel et al., 2012). The second 
method is more complex, requires more machines and greater space, and costs more than 
direct compression during the manufacturing process. These factors make direct 
compression the best option for achieving our goals.  
 Fast-disintegrating sublingual tablets 
SL tablets that are intended for the treatment of emergency conditions are required to meet 
certain criteria, aimed at allowing rapid drug release from the tablet and promoting 





be endowed with physical qualities that permit safe shipping and handling, which will 
enhance their deployability to farms and their use on battlefields. 
Significant challenges exist concerning the formulation of hard SL tablets that pass 
the friability test while achieving rapid disintegration and dissolution. Most fast-
disintegrating tablet formulations that disintegrate in less than 30 seconds are fragile and 
require special packaging to enable safe shipping and handling; this affects their portability 
and, therefore, their viability as an emergency dosage form. 
A FDST formulation was previously developed by Rawas-Qalaji and others as a 
platform for the SL delivery of epinephrine for the treatment of anaphylaxis treatment 
(Rachid, Rawas-Qalaji, Simons, & Simons, 2012; Rawas-Qalaji et al., 2006a, 2006b, 
2007). The formulation excipient(s) selection and ratios, and the effect of drug load and 
tablet dimensions on the epinephrine FDSTs’ characteristics, provided the foundation for 
the current project.  
Excipients selection 
FDSTs were composed of two cellulose excipients: microcrystalline cellulose (MCC) and 
low-substituted hydroxypropyl cellulose (L-HPC). Cellulose, which is an inert 
carbohydrate composed of β (1→4) linked D-glucose units, is the main component of the 
cell-wall in plants. However, the human digestive system cannot breakdown such glucose; 
ruminant mammals can digest cellulose by a fermentation process that enlists the help of 





MCC was first prepared in 1962 by Battista and P.A. Smith of the American 
Viscose Company. It can be produced in a range of particle sizes and shapes, with varying 
moisture content and porosity (Guy, 2009). The main filler used in our FDSTs was MCC 
grade PH-301, which is water-insoluble and has a particle size of 50 µm, with bulk density 
of 0.35 to 0.42 g/cm3 (Reier, 2000). This MCC grade was selected for its particle size and 
low moisture content. Most of the excipients chosen were of the same size range and 
density to ensure efficient mixing and to reduce content uniformity issues. Additionally, 
excipients with low moisture content were selected to enhance epinephrine’s stability as 
FDST; this was important, because epinephrine can be oxidized easily in the presence of 
moisture, heat, and light. 
Hydroxypropyl cellulose (HPC) is a water-soluble ether of cellulose in which the 
hydroxyl groups of the cellulose have been replaced with hydroxypropyl groups (Hapgood 
& Obara, 2009). In L-HPC, a small proportion of the cellulose hydroxyl groups are 
replaced with hydroxypropyl groups, which makes it a water-insoluble cellulose derivative 
(Hapgood & Obara, 2009). L-HPC has several grades of varying characteristics; the longest 
fibrous particle grade is LH-11, which was used in this work as a super-disintegrating agent 







The ratio between MCC grade PH-301 and L-HPC grade LH-11 was selected on the basis 
of previous studies in which a range of ratios was investigated (Bi et al., 1996; Watanabe 
et al., 1995). Watanabe et al. (1995) used a ratio of 9:1 MCC (PH-301): L-HPC (LH-11), 
finding that increasing LH-11 from 10% to 30% resulted in a reduction of the tablet’s 
hardness from 8 kgf to 6 kgf, while the disintegration time increased. Further increasing 
the LH-11 (beyond 30%) compromised the powder’s flowability (Watanabe et al., 1995). 
 Chapter Summary 
In this chapter, the OP toxicity mechanism, the epidemiology of OP toxicity cases, and the 
limitations of current OP toxicity treatments were discussed. Then, AS mechanism, clinical 
applications, and emergency dosage forms were reviewed. Explanations were given of the 
SL route anatomy, physiology, advantages, and disadvantages. The types of ODT 
formulations and the requirements for their application in emergency situations were 








 Chapter Overview 
When pursuing the objectives of this research project, the methods developed and used fell 
under the following four main categories: 
1. Qualifying AS analytical method. 
2. Formulating and manufacturing AS FDSTs and performing quality control testing. 
3. Evaluating the effect of the tablet size and dose load on the physical characteristics and 
quality of the AS FDSTs. 
4. Assessing, in vitro and ex vivo, the diffusion of AS from FDSTs. 
 Atropine Sulfate Analytical Method 
The USP has established a standardized quantification method for AS using high 
performance liquid chromatography (HPLC) (USP/NF, 2016g). Using the USP’s method, 
HPLC system qualifying procedures and AS calibration curves were performed, which will 
be described as follows. The qualification of the analytical method is essential for precise 





 HPLC system 
An HPLC system from Perkin Elmer™, model Series 200 (Waltham, MA), equipped with 
a UV/VIS detector, a pump, a column oven, a degasser, and an auto sampler, was used in 
this project. The chromatography was performed using reversed-phase µBondapak C18 
Column, 125Å, 10 µm, 3.9 mm X 300 mm (Waters Corporation, Milford, MA). The 




An acetate buffer was prepared by dissolving 4.1 g of sodium acetate into 2.9 mL of glacial 
acetic acid and diluting to 1 L with water. 
Mobile	phase	
The mobile phase for the elution of AS was composed of sodium hydroxide, and 
acetonitrile, purchased from EMD Millipore Corp., Billerica, MA. Tetra butyl ammonium 
hydrogen sulfate was purchased from Sigma Aldrich, Saint Louis, MO. The mobile phase 
was prepared by dissolving 5.1 g of tetrabutyl ammonium hydrogen sulfate into 50 mL 





The acidity of the mobile phase was adjusted to a pH of 5.5±0.1 with 5 N sodium 
hydroxide, using a pH meter (Orion Star®, Thermo Scientific), and filtered using 0.2 µm 
47mm Supor®-200 filter (Pall Corporation, Mexico). The pump flow rate was settled at 2.0 
mL/min.  
 Calibration curves 
For the quantification of AS samples, calibration curves were produced by plotting the 
AUC of known-concentration AS samples against their concentrations. A stock solution of 
AS (2 mg/mL) was prepared in deionized water using AS monohydrate (Sigma Aldrich, 
Saint Louis, MO, USA). A series of AS standards (200 µg/mL, 160 µg/mL, 80 µg/mL, 40 
µg/mL, 20 µg/mL, 10 µg/mL, and 5 µg/mL) were prepared from the stock solution. 
 HPLC analytical method qualification 
One of the basic requirements when undertaking any scientific research endeavor is to 
demonstrate the accuracy and reproducibility of the results obtained. To satisfy this 
stipulation, it is necessary to qualify the analytical instruments used. As part of the AS 
analytical method qualification, both the instrument and method were assessed to ensure 






The reproducibility of the HPLC system and UV detector were evaluated by analyzing 20 
µg/mL and 200 µg/mL AS multiple times (n=6) and by calculating the relative standard 
deviation (RSD%) for the injected low and high standard concentrations of the drug.  
The HPLC has an auto-sampling system that can withdraw samples from test vials. 
The volume of the sample withdrawn (injection volume) from the vial was selected 
according to the USP standard method. The accuracy of the injection volume was evaluated 
by calculating the RSD% (n=6) for increasing volumes of 10 µL, 20 µL, 40 µL, 60 µL, 80 
µL, and 100 µL from an AS standard solution of 20 µg/mL. The values of linearity of the 
injected AS standards at the various volumes were calculated. 
Method accuracy 
Personal variability was tested by performing the AS calibration twice (in the morning and 
evening) for three days to estimate intra- and inter-assay variability. The intra-assay 
variability was determined by comparing the results from the same day to evaluate whether 
variation could have resulted from running the HPLC at different times of the day (morning 
versus evening). The inter-assay variability was assessed by comparing the results from 
different days to evaluate the variability from day to day. To ensure the accuracy of the 
results even at very small concentrations, it was necessary to qualify the analytical 





concentration that can be quantified accurately and reproducibly. The minimum 
quantification limit of AS that uses HPLC with a UV detector was determined by injecting 
AS solutions of 5 µg/mL, 2.5 µg/mL, 1.25 µg/mL, and 0.5 µg/mL multiple times (n=5). 
The lowest concentration that had an RSD% < 5% was considered to represent the 
minimum quantification limit.  
 FDSTs’ Formulation, Manufacturing, and Quality Control Testing 
The composition of FDSTs’ formulation and the manufacturing techniques involved were 
first devised and published by Rawas-Qalaji et al. for epinephrine SL tablets (Rawas-Qalaji 
et al., 2006a, 2006b, 2007). This was adopted in the current project as a starting point for 
the development of AS FDSTs. AS, as the active ingredient, has different physiochemical 
properties from epinephrine. Because the dose required for the former is not the same as 
that for the latter, the drug load used and the manufacturing properties would be different 
for AS, leading to the requirement for intensive characterization and evaluation of the new 
AS FDSTs’ formulation. 
 Materials 
The API, AS, was purchased from Sigma-Aldrich (St. Louis, MO). MCC grade PH-301 
(Ceolus®) as a filler and L-HPC grade LH-11 as a superdisintegrant were provided by 





Japan), respectively. A lubricant, magnesium stearate, was purchased from Alfa Aesar 
(Heysham, Lancs, UK).  
 Formulation preparation 
All excipients and the API (Table 4) were sieved before mixing using an electrical sieve 
shaker (Cole-Parmer, Vernon Hills, IL) between sieves of mesh numbers 230-325 (62 µm 
- 44 µm) to avoid mixing segregation. The weight of the mixed batches was 60 g for tablets 
weighing 150 mg, and 30 g for tablets weighing 50 mg, which were sufficient to 
manufacture 300 tablets per batch to perform all tests. The AS was manually pre-mixed 
with the MCC via geometric dilution. The pre-mixture was then mixed with two thirds of 
the L-HPC quantity for four minutes using a three-dimensional manual mixer (Inversina, 
Somerville, MA). The remaining third of the L-HPC was manually pre-mixed with the 
magnesium stearate and added to the powder mixture to be mixed for an additional 30 
seconds. 
 FDSTs’ manufacturing 
Nine FDST batches were manufactured by direct compression using a rotary press (Mini 
Press-I, GlobePharma, New Brunswick, NJ). Bevel punches and dies (5”/16” and 3”/16”) 
were used to manufacture FDSTs weighing 150 mg (group A) and 50 mg (group B), 
respectively. The nine batches consisted of 0 mg AS (A1, B1) as a placebo, 2 mg AS (A2, 





different compression forces (B4a and B4b). Although B4a was compressed using the same 
compression force as B1, B2, and B3, B4b was compressed using a higher force to produce 






































































































































































































































































































































































































































































































































































 Evaluation of Physical Characteristics and Quality Control Testing 
For each batch of FDSTs, the powder mixture was tested for powder flow (PF) and 
moisture content. Manufactured FDSTs were tested for breaking force (BF), tensile 
strength (TS), friability (F), and content uniformity (CU), according to standard USP 
procedures (USP/NF, 2016a, 2016c, 2016e). Additional non-USP tests were developed and 
deployed to ensure reliable characterization of the manufactured FDSTs and accurate 
measurement of disintegration time (DT), percentage of drug dissolved (DD) (Rachid et 
al., 2011), wetting time (WT) (Bi et al., 1996; Rawas-Qalaji et al., 2006b, 2007), and water 
uptake (WU) of the developed and manufactured FDSTs. 
 Powder flow (PF) test 
The direct compression manufacturing method requires the powder mixture to be free-
flowing to ensure uniform weight and content of tablets. The PF (n=3) was examined by 
measuring the angle of repose for the A4 and B4 batches, which contained the highest AS 
content and would therefore have the poorest flow properties. A precisely weighed amount 
of powder was poured from a funnel over a clean flat surface with a diameter of 7 cm, 
using a glass beaker bottom. The height of the funnel tip was 10 cm from the flat surface 
and the funnel’s orifice was 8 mm. The powder formed a cone shape on the flat surface. 






measuring the angle directly using a specialized protractor (Figure 9) and by using 






		                                                                                                     (1)  




Figure 9. Measuring the angle of repose using a protractor. 
 
 Moisture content (MC) test 
The MC of a mixed powder can affect the API’s stability and powder flowability. 
Therefore, the MC of the powder for each AS FDSTs batch was analyzed using a Halogen 
Moisture Analyzer HE73, METTLER TOLEDO® (Sonnenbergstrasse, Schwerzenbach, 
Switzerland). A quantity of powder weighing 1 g (n=3) was sprinkled on the heating pan 





moisture in the powder tested. The MC (%) was reported by the machine using the 
difference in the powder weight after heating. The samples were discarded after testing. 
 Tablet dimensions measurement 
The dimensions of the tablets are an essential parameter as they determine the product’s 
tensile strength. The bevel-shaped FDSTs’ dimensions were diameter (D), thickness at the 
center (TC), and thickness at the wall (TW). Mean ± SD for six tablets from each batch 
was measured using a digital caliper (VWR, Randor, PA). 
 Content uniformity (CU) test 
A CU test is required by the USP for tablets containing less than 25 mg of the active 
ingredient per unit or less than 25% of tablet weight to ensure the uniformity of drug load 
per tablet (USP/NF, 2016c). Therefore, 10 out of 30 randomly selected tablets were 
individually analyzed for drug content using HPLC with UV detection (Perkin Elmer, 
Waltham, MA, USA), as described below.  
AS was extracted from the FDSTs for the HPLC assay by dissolving and vortexing 
each tablet in 10 mL of distilled water for 1 minute. An aliquot was then filtered using 0.45 
µm nylon syringe filters (VWR, Randor, PA) before injecting into the HPLC. The 
acceptance value (AV) of L1 (15% or less) was calculated, which is considered acceptable 





 Friability (F) test 
The tablet’s F is the percentage of its weight loss upon completion of the F test (USP/NF, 
2016a). It is designed to imitate the effects of handling and shipping upon regular tablets. 
The maximum weight loss permitted, according to USP guidelines, is no more than 1.0% 
of the original weight. Tablets weighing no less than 6.5 g were dedusted and placed in the 
F-tester’s drum (Vanguard, Spring, TX). Tablets were tested for 100 rounds at 25 rpm 
according to the USP guidelines. At the end of the test, the tablets were removed, dedusted, 
and weighed again (USP/NF, 2016e).  
 Breaking force (BF) test 
The tablet’s BF is the pressure (measured in kilogram force) needed to break it into two 
halves. This is one of the standard USP tests (USP/NF, 2016e). According to the procedure 
proscribed, six randomly selected tablets were placed individually in the middle of the 
metal bar on the tablet hardness tester model, LIH-3 (Vanguard, Spring, TX). The bar will 
gradually apply pressure on the tablet until the tablet breaks. The hardness tester will record 





 Tensile force (TS) test 
The tablet’s TS is the BF divided by its surface area; this is another of the USP’s standard 
tests (USP/NF, 2016e). The TS of convex tablets was calculated according to the USP 













         (2) 
σx is the TS; F is the BF; D is the tablet diameter; H is the tablet thickness; W is the central 
cylinder thickness (tablet wall height). 
	
 Disintegration time (DT) test 
DT was measured using a previously developed apparatus to accurately measure the DT of 
FDSTs or ODTs with permissions (Appendix: Copyrights Permissions) (Aodah, Bafail, & 
Rawas-Qalaji, 2016). The apparatus is composed of a USP-standard dissolution basket 
connected to a rotating shaft at 60 rpm and immersed into a 2 mL-volume water bath 
maintained at 37C°. The disintegration end point was recorded visually (n=3) using a 
stopwatch when no tablet residues were left in the basket (Aodah, Bafail, & Rawas-Qalaji, 






Figure 10. Image of disintegration apparatus. 
 
 Wetting time (WT) test 
The wetting test was performed according to a previously reported method (Bi et al., 1996; 
Rawas-Qalaji et al., 2006b, 2007). In brief, 6 tablets were randomly selected from each 
batch and placed individually in the middle of a double-layered wetted and drained paper 
towel in a plastic dish. The WT (endpoint) was recorded using a stopwatch when the water 






 Water uptake (WU) test 
The following procedure was developed to measure WU. One tablet was placed on a plastic 
weighing dish positioned on an analytical balance, and the initial weight was recorded. 
Using a 1 mL glass pipette, water was delivered dropwise on the center of the tablet while 
the water volume dispensed and the tablet weight after each drop until water started to ooze 
out of the tablet body was recorded (n=6) (Figure 11 C). The percentage of WU per tablet 




	×100       (3)  
 
 
Figure 11. Wetting and water uptake tests of FDSTs. 
A: an image of dry FDSTs before starting the test; B: an image of FDSTs placed on a wet 





 Drug dissolution (DD) test 
A previously developed and evaluated dissolution apparatus, which imitates SL conditions, 
was used for this test (Rachid et al., 2011). In short, the apparatus was assembled from a 
donor chamber, which was connected to a receiver tube, with a filter membrane at 0.45 µm 
(VWR, Randor, PA) in between; the apparatus was then connected to a vacuum (Figure 
12).  
Six tablets were randomly selected from each batch for the drug dissolution test. 
Each tablet was dropped into the donor chamber, which contained 2 mL of distilled water. 
After 60 seconds, the vacuum was activated to instantaneously suction all dissolved AS 
into the receiving tube. Undissolved AS particles were retained on the filter membrane. 







Figure 12. An illustrative scheme of the dissolution apparatus (Rachid et al., 2011). 
Reprinted with permission (Appendix: Copyrights Permissions). 
 Diffusion and Permeability Studies 
The AS in vitro and ex vivo diffusion from FDSTs was investigated to explore the 
feasibility of AS SL permeation, and to evaluate the effect of the tablets’ physical 
characteristics on AS diffusion. 
 Materials 
Static vertical-jacketed Franz cells (Figure 13) with a receptor chamber volume of 20 ± 
0.1 mL (PermeGear Inc., Hellertown, PA) were used to perform both in vitro diffusion and 
ex vivo permeation studies. The in vitro diffusion of AS from FDSTs was evaluated using 





Rancho Dominguez, CA). The ex vivo permeability of AS through a SL membrane was 
assayed using a PSM. Frozen lower jaws of male adult domestic pigs (Sus domesticus) 
were purchased from a local abattoir, and the thin epithelial membrane was separated from 
the underlying connective and fat tissues in the floor of the mouth using a previously 
established surgical technique (Rawas-Qalaji, Werdy, & Rachid, 2015). The dissected 
sublingual membranes were inspected visually for integrity and refrozen in aluminum foil 
at –20˚C before being thawed at room temperature to be used within a maximum of 30 
days.  
 






 Procedure  
Before each experiment, the excised SL membranes were thawed at room temperature and 
clamped between the donor and the receptor chamber of each cell. A phosphate buffer, pH 
6.5, representing the average pH of saliva (pH 5.8–7.5) (Zhang et al., 2002), was poured 
into the receptor chamber using a magnetic stirrer as the diffusion medium. The 
temperature of the circulating water was set at 37° C ± 1° C and the mounted epithelial 
membranes were equilibrated for 30 minutes. Air bubbles were removed from the receptor 
chambers and cells were checked for leaks.  
The in vitro and ex vivo studies (n=4) were performed for A2, A3, A4, B2, B3, and 
B4a FDSTs and compared to the diffusion of AS 2 mg solution (1 mg/mL) as a reference. 
B4b was excluded from the diffusion studies based on its physical evaluation. AS FDSTs 
were placed in the donor chamber at time 0 (T0) with an aliquot of 2 mL of phosphate 
buffer to imitate the average saliva volume in the oral cavity (1 mL/min, for 2 minutes) and 
to facilitate tablet disintegration and dissolution. Aliquot samples at 200 µL were collected 
from the receptor chamber at intervals of 5, 10, 15, 20, 30, 45, 60, 75, and 90 minutes using 
needles of 22 (gauge) × 6 inches (length) (Cadence Inc., Cranston, RI) and 1 mL syringes. 





 Effect of tablet size on atropine sulfate’s concentration gradient 
The concentration difference created within the Franz cells’ donor chambers as a result of 
AS dissolution and diffusion was measured for A4 and B4a to evaluate its effect on the 
concentration gradient across the diffusional membrane and AS influx. Each tablet (n=4) 
was placed in the middle of the donor chamber, which was filled with 2 mL of phosphate 
buffer (pH 6.5). Aliquots of 200 µl volume were withdrawn from two sites, the tablet 
contact area (central area, C), and the donor chamber wall’s contact area (lateral area, L), 
within 20 and 90 minutes of inserting the tablet (Figure 14). Samples were analyzed for AS 
concentration using HPLC. The ratio of central to lateral (Ratio C/L) AS concentration was 
calculated to determine the effect of tablet size on AS concentration. This was because of 




















































































































































































































 Data Analysis 
The mean (±SD) BF, TS, DT, WT, WU, DD, and CU were calculated for each formulation. 
The mean (±SD) cumulatively diffused AS per area, J AUC0–90 (µg/cm2), was calculated 
for each FDST formulation. The mean AS influx, J (µg/cm2/min), was calculated from the 
slope of each graph. In addition, AS permeability, P (cm/min), was calculated by dividing 
J by the initial AS concentration in the donor chamber at T0. To further analyze AS FDSTs’ 
physical property effects on diffusion behavior, the J AUC0–15 was measured separately 
and compared using an analysis of co-variance (ANCOVA) model to normalize the DT 
differences between group A and group B AS FDSTs. Data were statistically compared by 
two-way analysis of variance (ANOVA), ANCOVA, and the Tukey-Kramer test using 
NCSS statistical software (NCSS, Kaysville, UT). Differences were considered statistically 
significant at p < 0.05. For each endpoint measured, the minimum number of replicates 
that were performed was 3 (n ≥3). 
 Chapter Summary 
In this chapter, the necessary methods to investigate the project hypothesis were discussed. 
The various approaches used to evaluate each objective were described in detail. An HPLC 
system with UV detection was qualified and used to analyze and quantify AS samples. 
Nine batches of AS FDSTs were developed, formulated, and manufactured and their 





and TS). Further tests were customized and either developed or adapted (DT, WT, WU, 
and DD) for more accurate characterization of the FDSTs. AS diffusion and permeation of 
various AS FDSTs formulations were evaluated using Franz diffusion cells. Finally, the 










 Chapter Overview 
In this chapter, the results of all the tests performed in the methods section are summarized. 
The results of the HPLC method qualification, physical characteristics of FDSTs, and AS 
diffusion studies are outlined, with greater emphasis on the more significant outcomes. 
Tables were created to capture all test results and figures were plotted to compare the 
findings from the physical tests and diffusion studies.  
 HPLC Method Qualification 
AS was eluted at 5.5 minutes; an overlay of HPLC chromatograms for AS concentrations 






Figure 15. HPLC chromatogram of AS. 
The chromatograph of AS using the standardized USP HPLC analytical method (USP/NF, 
2016f), showing a consistent peak appearance at a retention time of 5.5 minutes. 
 
 Atropine sulfate calibration curves 
Calibration curves were linear, with correlation of coefficients (R
2
) of > 0.99. The mean 






Figure 16. AS calibration curve using HPLC. 
The mean AUC±SD (n=6) of AS standard solution at 5 µg/mL, 10 µg/mL, 20 µg/mL, 40 
µg/mL, 80 µg/mL, 160 µg/mL, and 200 µg/mL. 
	
 Instrumental accuracy 
The Relative standard deviation percentages (RSD%) of the system’s reproducibility at 
concentrations of 20 µg/mL and 200 µg/mL (n=6 each) were 1.07% and 0.14% 
respectively. The instrument injection of 20 µg/mL, using increasing injection volumes, 






























Figure 17. The accuracy of the autosampler injection volume. 
 
 Method accuracy 
The intra- (n=3) and inter-assay (n=3) RSD percentages for 20 µg/mL were 0.81 and 1.97 
respectively, while for 200 µg/mL they were 0.44 and 0.78 respectively. The minimum 
































 Physical Characteristics of FDSTs 
 Powder flow (PF) test 
The powder blends of A4 and B4 had a passable flowability according to the USP, with an 
angle of repose of 44˚ and 45˚ respectively (USP/NF, 2016d).  
 Moisture content (MC) test 
All batches of AS FDSTs batches’ powder blends were tested for their MC; the results are 
listed in Table 5. 
 Tablets’ dimensions 
Tablets’ diameter (D) 
The use of two differently sized sets of dies produced tablets of two distinct sets of 
dimensions and physical characteristics. Group A FDSTs (the larger size) were 
manufactured using a die of 5”/16” D, resulting in tablets with a mean D of 7.95 ± 0.0 mm, 
while group B FDSTs (the smaller size) were produced using a die of 3”/16” D, yielding 






The use of different tablet sizes, weights, and loads resulted in variations in thickness. The 
thickness of bevel-shaped tablets was measured at two points: at the center (TC) and the 
wall (TW). Mean ± SD of the TC and TW are listed in Table 5. 
 Content uniformity (CU) test  
The maximum acceptance value (AV) for CU for these tablets was 15 according to the 
USP (USP/NF, 2016c). All tablet batches met the USP’s criteria for drug CU testing, with 
AV of ≤ 15. Mean (± SD) tablets’ CU and AV for all FDST formulations are listed in Table 
5.  
 Friability (F) test  
The maximum weight loss allowed by the USP for the F test is no more than 1% (USP/NF, 
2016a). All FDST batches were tested and passed the F test, with no more than 0.32% 





















































































































































































































































































































































































































































































































































 Breaking force (BF) test  
The BF test results showed that group A FDSTs were not affected (p < 0.05) by an 
increasing AS load, resulting in no significant differences among the various AS doses in 
group A FDSTs (2.8–3.0 kgf). However, group B was significantly (p < 0.05) affected by 
increasing the AS dose (1.5–3.3 kgf). Mean (± SD) FDSTs’ BF results are reported in  
Table 6. The results are also summarized in comparison to the TS results in Figure 18. 
 Tensile strength (TS) test  
The TS was not affected (p > 0.05) by increasing the AS load in group A FDSTs; 
however, the TS was reduced when the AS load was increased in group B FDSTs and 
became significantly different (p < 0.05) when the AS dose reached 8 mg (B4a), even 
though the values of TS group B FDSTs were significantly higher (p < 0.05) than for group 
A, except for B4a. Mean (± SD) FDSTs’ TS results are reported in Table 6. The results are 




































































































































































































 Disintegration time (DT) test  
Despite the higher TS in group B FDSTs, the values of DT of group B were 
significantly shorter (p < 0.05) than those for group A and were not affected (p > 0.05) by 
increasing the AS load, even for B4a, which had significantly lower (p > 0.05) BF and TS. 
That said, the DT of group A FDSTs was significantly increased (p < 0.05) by increasing 
their AS load despite the fact that no significant changes were detected in their BF and TS 
as a result of increasing their AS load. However, the DT of A2 (2 mg AS) was significantly 
shorter (p < 0.05) than that of the A1 (placebo). In addition, increasing the compression 
force of the 8 mg FDSTs (B4b) to yield a similar tablet hardness delayed DT significantly 
(p < 0.05). Mean (± SD) FDSTs’ DT results are reported in Table 6. The results are also 
summarized in comparison to WT results in Figure 19. 
 Wetting time (WT) test 
Additionally, although the FDSTs’ WT was not significantly affected (p > 0.05) by 
increasing the AS load in group A FDSTs, the same measure significantly retarded (p < 
0.05) the WT in group B tablets. The WT of B4a, however, was significantly shorter (p < 
0.05) than that of B3. However, increasing the compression force of the 8 mg FDSTs (B4b) 
to result in a similar tablet hardness delayed DT significantly (p < 0.05). Mean (± SD) 
FDSTs’ WT results are reported in Table 6. The results are summarized in comparison to 











































































































































































































 Water uptake (WU) test 
The WU was significantly reduced (p < 0.05) as the AS load was increased in group 
B FDSTs. Group A FDSTs were less affected (p > 0.05) by the increase. Mean (± SD) 
FDSTs’ WU results are reported in Table 6; the results are also summarized in comparison 
to DD results in Figure 20. 
 Drug dissolution (DD) test 
The dissolved percentage of AS from AS FDSTs in the first 60 seconds (DD %) was not 
affected (p > 0.05) by increasing the AS load in group A FDSTs. Although it was also not 
affected (p > 0.05) in group B FDSTs, the increase did affect their DT, WU, and WT 
(Table 6). Compared to group A, the DD percentage in group B FDSTs was significantly 





























































































































































































































































































































































































































































































































































































































































































































































 Atropine Sulfate Diffusion and Permeability Studies Results 
The mean (± SD) cumulative AS in vitro and ex vivo diffused amount (µg) per area (cm2) 
versus time (min) are plotted in Figure 21 and 22, respectively. The in vitro and ex vivo 
JAUC0–90 in both groups, A and B FDSTs, were linear (R2 ≥ 0.96) (Figure 23). Increasing 
their AS load resulted in a significant increase (p < 0.05) in their JAUC0–90, except for the 
ex vivo JAUC0–90 of B2 and B3 (Table 8). In addition, the in vitro and ex vivo AS influxes 
(J) in both group A and B FDSTs were linear (R2 ≥ 0.96) (Figure 24), which resulted in a 
significant increase (p < 0.05) as their AS load became greater (Table 7 and 8).  
Without accounting for the difference in the DT between group A and B FDSTs, 
their overall in vitro and ex vivo JAUC0–90 did not result in a significant difference (p > 
0.05) at the various AS doses, except for in vitro JAUC0–90 B3 (Table 7), which was higher 
than A3. Similarly, no significant differences were detected (p > 0.05) in both in vitro and 
ex vivo AS influxes between group A and B FDSTs, except for in vitro J of B4a (Table 7), 
which was higher than that of A4. Additionally, no differences were seen in the 
permeability coefficient (p > 0.05) between group A and B FDSTs for both 4 and 8 mg AS 
doses (Table 8). 
 
As a result of the significant differences in the DT between group A and B FDSTs, 
only the in vitro and ex vivo cumulative AS diffusion during the initial 15 minutes (JAUC0–





normalizing the JAUC0–15 means for various tablets’ DTs using an ANCOVA statistical 
analysis test, the ex vivo JAUC0–15 of B3 and B4a were significantly higher (p < 0.05) than 
for A3 and A4, respectively, but no such difference was detected (p > 0.05) between A2 
and B2 (Figure 25). In addition, the in vitro JAUC0–15 resulted in no significant differences 








































































































































































































































































































































Figure 23. AS dose linearity for in vitro and ex vivo cumulative diffusion. 
Mean ± SD for in vitro and ex vivo AS cumulative diffusion (JAUC0-90) of FDSTs 
containing AS at 2 mg, 4 mg, and 8 mg, and weighing 150 mg (A2, A3, and A4, 







Figure 24. AS dose linearity for in vitro and ex vivo diffusion influx. 
Mean ± SD for in vitro and ex vivo AS influx (J) of FDSTs containing AS at 2 mg, 4 mg, 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Atropine sulfate concentration gradient study results 
The AS concentration measured at the central area (C) of the donor chamber of a Franz 
cell in which a B4a FDST had been placed for 20 minutes was significantly higher (p < 
0.05) than with A4 FDSTs (Figure 26). Also, the mean ratio of AS concentration at C to 
its concentration at the lateral area (L) of the donor chamber, for A4 FDSTs (ratio C/L 1.2 
± 0.07), was significantly higher (p < 0.05) than for B4a FDSTs (ratio C/L 0.95 ± 0.06) 90 







































































































































































































 Chapter Summary 
In this chapter, the instruments and USP method used for the analysis of AS and their 
accuracy testing, the physical characteristics of FDSTs, and the AS diffusion and 
permeation studies were reported. AS calibration curves were successfully constructed 
using the standardized USP analytical method. Both the analytical instrument and the 
method demonstrated high accuracy. The results for PF and MC for the powder mixtures 
from various batches were reported. Following FDSTs manufacturing, their dimensions, 
as well as the results of the CU, F, BF, TS, DT, WT, WU, and DD tests, were reported. 
Then, the results of the diffusion and permeation studies of AS FDSTs using a synthetic 
membrane and PCM, respectively, were reported. Finally, the results of the effect of tablet 










In this study, the potential of using a previously evaluated route (Comley, Galletly, & Ash, 
2000; Heisler et al., 2013; Hyson, Johnson, & Jog, 2002; Kanto & Pihlajamaki, 1986; 
Protus et al., 2013; Rajpal et al., 2010; Rapoport, 2010; Volz-Zang et al., 1995), and an 
existing FDST formulation (Rawas-Qalaji et al., 2006b) for the SL delivery of AS in the 
treatment of OP toxicity were investigated. SL tablets that are meant for treating emergency 
conditions should meet certain criteria that allow for rapid drug release from the tablet and 
complete drug dissolution in small saliva volumes within a very brief period (Nayak & 
Manna, 2011; Wang & Chow, 2014; Washington & Washington, 2001; Zhang et al., 2002). 
Such tablets should also possess physical qualities that allow them to withstand shipping 
and handling, which will enhance the feasibility of their use by the military on battlefields 
and by civilians on farms for pesticides poisoning as well as for a range of other clinical 
conditions (Aodah et al., 2016; Cunningham, Baughman, Peters, & Laurito, 1994; Kroboth, 
McAuley, Kroboth, Bertz, & Smith, 1995; Price et al., 1997; M. Rawas-Qalaji et al., 2015; 





To achieve this aim, four doses of AS FDSTs in two sizes (A and B) were 
manufactured and their physical characteristics were tested via the standard USP tests (CU, 
F, BF, and TS), as well as our own developed and modified tests (DT, WT, WU, and DD) 
to ensure that the stringent criteria for SL drug delivery are met. The diffusion of AS from 
these FDSTs was investigated in vitro, using a synthetic membrane, and ex vivo, using 
excised PSM, to evaluate the effect of varying the tablets’ characteristics (by using 
different sizes and drug loads) on AS SL diffusion. The effect of tablet size on the 
concentration gradient of AS was also investigated to confirm its effect on AS 
permeability. 
 AS FDSTs’ Physical Characteristics 
Although AS is a freely water-soluble salt (2.1 g/mL) (RSC, 2013), it had a detrimental 
effect on the FDSTs’ physical characteristics. Whereas AS constituted only about 1–5% of 
group A FDSTs, this figure was far higher (4–16%) in group B FDSTs as a result of the 
difference in the tablets’ dimension and weight. Therefore, to evaluate the effect of AS on 
the FDSTs’ physical characteristics, the same manufacturing settings were used for both 
groups. These settings included the tablet hardness output gauge, which determines the 
amount of pressure applied by the upper and lower dies on the formulation powder. Since 
compression force readings were not available, the BF of placebo tablets was used to 





Increasing the AS load did not negatively affect the BF of group A FDSTs, and 
significantly lowered that of group B tablets only when it constituted 16% of the tablet’s 
weight (B4a) (Figure 18). This emphasizes the high dilution potential of this formulation. 
The reduction in the BF of B4a can be largely attributed to the poor AS compressibility 
profile; as its content was increased, its dimensions reduced and the excipient content 
became smaller to form a hard, compact tablet. To evaluate the significance of the impact 
occasioned by increasing the AS load, which reduced the excipients content of these 
FDSTs, another batch of AS at 8 mg (B4b) was compressed at a higher force, resulting in 
a similar hardness. 
Although the BF of both FDST groups was the same, excepting B4a, the BF 
measurement did not take into consideration the differences in tablet dimensions and the 
amount of force applied per area, which explained why similar BF results were seen for 
two distinct tablet sizes that were compressed at the same level of force (Figure 18). 
Therefore, the tensile strength was calculated to compare the two tablets’ sizes (Figure 
18). Reducing the size resulted in a TS that was 2.5 times greater, since the same amount 
of force was being used to compress a smaller tablet (Figure 18).  
The AS load negatively impacted the TS as the AS dose was increased in group B 
FDSTs. In contrast, group A FDSTs could tolerate the dose increase without their TS being 
affected (Figure 18). These results underlined the influence of the tablets’ dimensions and 
excipient content of FDSTs on their physical characteristics and dilution potential. 
The current USP method cannot detect or discriminate between small differences 





sensitive test for pinpointing differences in DT between almost identical ODT formulations 
or when changing the dose or dimensions of the same formulation. Rapid disintegration is 
one of the key attributes of a successful ODT formulation and can impact the rate and 
extent of drug dissolution and absorption, especially when the timeframe available for drug 
absorption is limited, as in SL administration. For this purpose, a previously developed, 
sensitive disintegration test was used, which is capable of detecting minor differences in 
DTs during ODTs’ or FDSTs’ formulation, development, and optimization (Aodah et al., 
2015). Despite group A’s high tolerance of AS load, this test could detect significant delays 
in their disintegration as the AS load was increased. In addition, the disintegration of group 
B FDSTs was significantly faster than that of group A and was not negatively impacted by 
increasing AS load (Figure 19). This can be explained by their smaller dimensions, which 
required less time for water to pass through, as well as by the fact that less interparticulate 
bonds were formed between granules in group B FDST’s powder, which had to be broken 
up. The superdisintegrant was also evenly distributed internally within the tablet, as well 
as being positioned externally using a two-step mixing order, which facilitated rapid 
disintegration. Similar results have previously been observed when testing various tablet 
dimensions (Rawas-Qalaji et al., 2007).  
The wetting test returned highly similar results to those of the disintegration test. 
This test deployed a more challenging water volume and relied on capillary diffusion of 
water from just one side to the entire tablet, which is considered a more accurate predictive 
tool with regards to the tablet’s behavior in the SL area and under the tongue. Loading 





low percentage of AS per tablet; in addition, sufficient excipients were available to 
maintain high tablet porosity, which ensured rapid water penetration throughout the tablet 
(Figure 19). Conversely, the WT of group B FDSTs was delayed as AS load was increased, 
because of the lower excipient content per unit. Due to the significantly low BF of B4a, its 
WT was significantly faster than that of B3 (Figure 19). That said, the WTs of both groups 
were nevertheless considered very fast. These results suggest that the formulations had 
high porosity despite their differences. 
The WU test assessed the amount of water that could be absorbed and held by a 
tablet. The ability of the tablet to take in and hold sufficient water to dissolve AS reflects 
two properties: the excipients’ expandability and the effect of AS on tablet expansion or 
swelling. The amount of water that can be held by the tablet will be used to disintegrate the 
tablet and dissolve AS. Since AS is freely soluble, increasing its dose will reduce the 
FDST’s ability to swell, which compromises its ability to absorb and hold more water. 
Group A FDSTs were less affected by the addition of greater levels of AS to the tablet as 
a result of their higher excipient content, compared to group B FDSTs, which had 
significantly lower WU (Figure 20).  
Finally, the DD was deployed to measure the percentage of the drug that could be 
released from the FDST and dissolve within the first 60 seconds.  This was accomplished 
using a method previously developed and validated by our group that simulated drug 
dissolution in the oral cavity, lacked agitation, and relied on a dissolution medium’s volume 
that resembles that of saliva (Rachid et al., 2011). Despite the significant reduction in WT 





parameters did not correlate with their DD. Instead, the FDSTs of group B had a 
significantly higher DD than their group A FDSTs, which correlated closely with their DT 
as opposed to WT or WU (Figure 21). It can be concluded that the DT of an FDST 
containing a water-soluble drug can be a useful predictor for its rate of dissolution.  
 AS FDSTs’ Diffusion Characteristics 
Although significant differences were present between group A and B FDSTs in their 
physical characteristics, most notably their DT and DD, these differences did not translate 
into any impact on AS in vitro diffusion and ex vivo permeability as performed over 90 
minutes. Both in vitro and ex vivo studies showed no significant differences in the 
cumulative diffused AS (JAUC0–90) and influx (J) between group A and B FDSTs (Table 
7 and 8), which also had similar ex vivo permeability (Table 8). In addition, increasing the 
AS dose resulted in a linear increase in JAUC0–90 and J in both groups, which indicated a 
passive SL AS transport mechanism within the dose range used in this study.  
Since the DT of FDSTs is the main physical characteristic that causes a significant 
difference in AS dissolution, this difference became irrelevant or obsolete and was not 
statistically accounted for when the AS diffusion occurred over a prolonged period that far 
exceeded the time required for FDSTs’ complete disintegration and DD. This prolonged 
diffusion time may be acceptable for ODT formulations aimed at delivering the drug to the 
GIT for absorption, or for ODT formulations’ comparison, but not for FDSTs intended for 





which are intended to be swallowed with the saliva to reach the GIT, will most likely not 
impact their rate and extent of drug absorption. However, this may not be the case for drugs 
produced with ODT formulations and that are meant to be absorbed over a short period, 
such as SL administration for the treatment of emergency conditions.  
Ideally, the SL administration and retention of the tablet, or the disintegration of its 
fine particles under the patient’s tongue, should not take more than 1–2 minutes to avoid 
swallowing the API in error and to enhance patient compliance. During this time, a 
therapeutically sufficient amount of the drug should have been released, dissolved, and 
absorbed. An initial drug amount is permeated and absorbed immediately through the SL 
mucosa, before the remaining, permeated but not yet absorbed, drug accumulates in the 
submucosal layers of the SL membrane, which has a thickness of about 180 mm (Wang & 
Chow, 2014). Any released and dissolved drug that exceeds the SL epithelial cells’ 
absorption capacity during this short period of SL administration will not be absorbed. This 
transport mechanism-related explanation was also adopted in our previous SL animal 
studies to explain the obtained plasma results for epinephrine (Rawas-Qalaji et al., 2006b; 
M. M. Rawas-Qalaji et al., 2015).  
Because the period immediately following the SL drug administration is critical for 
AS diffusion and SL absorption, the in vitro and ex vivo AS diffusion data of various AS 
FDSTs were recalculated for only the first 15 minutes of diffusion (JAUC0–15). Also, the 
means of JAUC0–15 were statistically reanalyzed and their DT was considered as a covariate 





exact effect of DT as a main variable for the impact of FDSTs’ physical characteristics on 
AS diffusion, which can affect its SL absorption and relative bioavailability.  
The in vitro AS JAUC0–15, using cellulose synthetic membrane, did not result in a 
significant difference between group A and B FDSTs (Figure 25), because no equilibrium 
needs to be established across the synthetic monolayer membrane and there is no 
requirement to overcome permeability resistance by ensuring that a sufficient 
concentration gradient is established across the synthetic membrane. Therefore, small 
differences in the concentration gradient, caused by variations in the tablets’ DT, did not 
result in a significant difference in AS JAUC0–15 between group A and B FDSTs. However, 
the ex vivo AS JAUC0–15 using excised PSM did result in significant differences between 
the groups, excepting the AS 2 mg FDSTs (Figure 25). At higher AS doses, smaller FDSTs 
(group B) resulted in faster tablet disintegration, which in turn effected quicker AS release 
and higher AS dissolution, creating a high concentration gradient across the SL multilayer 
mucosal membrane and promoting more far-reaching AS permeation. In contrast, at lower 
AS doses B2 did not enable the release and dissolution of sufficient AS, compared to B3 
and B4a, to create a concentration gradient high enough to illustrate the impact of the 
difference in DT between B2 and A2 FDSTs. This resulted in a significant difference in 
the AS diffusion. Additionally, the magnitude of the difference in DT between B2 and A2 
FDSTs was only about 5 seconds, compared to around 20 seconds for higher AS doses, 
which may have also contributed to the difference in the amount of AS released. 
Another test was performed to confirm the existence of a detrimental difference 





was necessary because of the significant differences in their physical characteristics, 
namely DT and DD, which impacted the concentration gradient created and thereby made 
a significant difference in their AS diffusion. AS concentration was measured in the central 
(C) and lateral (L) areas of the donor chamber of the Franz cell for both A4 and B4a FDSTs, 
as examples of both groups’ tablet. The “C” sampling location was immediately adjacent 
to the disintegrated FDST and represented AS concentration in the tablet’s diffusional or 
“stagnant” layer, while the “L” sampling location was at the furthest area from the tablet 
in the donor chamber. Samples collected at 20 minutes represented AS concentration 
before equilibrium was attained within the chamber, as well as the AS amount available 
for absorption during the initial AS diffusion, and can be correlated to the rate and extent 
of drug absorption in the treatment of emergency conditions. On the other hand, samples 
collected at 90 minutes, which was a sufficient time for equilibrium to be reached in the 
donor chamber, represented the AS diffusion over an extended period. It is likely that this 
has no significant clinical value for the treatment of emergency conditions using the SL 
route, which is suitable for rapid drug administration. 
The AS concentration in the diffusional layer of B4a FDSTs at 20 minutes was 
found to be significantly higher than in the same layer of A4 FDSTs (Figure 26). These 
results clearly demonstrate that the concentration gradient created across the diffusional 
membrane by group B FDSTs in the central area close to the tablet was significantly higher 
than group A FDSTs. This discrepancy was mainly due to the difference in their physical 
characteristics, resulting in a significant difference in their AS diffusion during its first 15 





FDSTs was almost 1, indicating that AS had reached equilibrium within the donor 
chamber. However, it was almost 1.2 in A4 FDSTs, pointing to a delay in AS reaching 
equilibrium, which was caused by the longer DT of A4. In comparison to B4a, and as more 
time elapsed, a higher concentration gradient was created by A4 at the central part of the 
donor chamber during the extended time of AS diffusion. This explains the lack of an 
overall significant difference in the AS diffusion between groups A and B over 90 minutes, 
JAUC0–90. A higher AS diffusion occurred from group A FDSTs during the second part of 
the diffusion time, at 40 minutes for A4 and 50 minutes for A3. This was caused by the 
higher concentration gradient at the central area, which compensated for the tablets’ lower 
AS diffusion during the initial part of the diffusion period that was a result of their slower 
disintegration (Figure 26). 
 Recommendations for Future Studies 
In the interests of enhancing AS permeability and absorption, further studies are 
recommended to evaluate the effect of the saliva pH on drug ionization, as well as the 
potential for modifying the pH. Also, penetration enhancers have been reported to enhance 
SL permeability, which calls for further studies to assess the effect of a range of penetration 
enhancers at various concentrations, on AS permeation. To further confirm the effect of 
changing FDSTs’ dimensions on SL AS absorption, future animal dose ranging studies 
should be planned to evaluate various FDSTs’ sizes to optimize these novel AS FDSTs and 






In this study, various AS doses into smaller FDSTs weighing 50 mg were successfully 
formulated, which resulted in complete tablet disintegration in ≤ 15 secs and AS dissolution 
≤ 60 secs without compromising the FDSTs’ physical characteristics. The SL diffusion of 
AS from these FDSTs was feasible and resulted in a linear AS diffusion as the dose was 
increased. FDST of smaller dimensions can result in faster disintegration and higher DD, 
which can significantly enhance SL drug diffusion. The DT of FDSTs, using a sensitive 
disintegration test, can be used as a promising predictor for the dissolution and diffusion 
of water-soluble drugs.  
 This study discussed the interaction between physical characteristics and diffusion 
behavior of AS from a fast- disintegrating dosage form. In addition, using a previously 
successful formulation (for epinephrine) has established that formulation as a platform for 
further studies. However, the main limitation of this study was the absence of in vivo animal 
studies that can enlighten the direction of the future development in AS FDSTs. 
The clinical significance of these novel AS FDSTs is that they have the potential to 
be used as an alternative, non-invasive, and easily administered dosage form for the 
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Figure 8: The anatomy of the sublingual area (Ghandi & Robinson, 1994). 
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Figure 12. An illustrative scheme of the dissolution apparatus (Rachid et al., 2011). 
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